The highest-conviction view is bearish on Kodiak Sciences (KOD): its eye-disease drug may struggle to gain adoption if trials do not show better outcomes or a meaningful dosing advantage over Eylea. Before acting, monitor upcoming trial results and compare efficacy and injection frequency; future outcomes remain uncertain. The speaker mentioned considering a short, but $15 and $10 were speculative downside levels, not formal price targets.

Kodiak Sciences (KOD)

• The discussion was strongly bearish on Kodiak’s eye-disease drug program, including KSI-501. The speaker argued that the treatment had repeatedly failed to show an advantage over Eylea, a commonly used comparator that the speaker described as available in biosimilar form.
• The speaker criticized the trial results and dosing burden, saying Kodiak’s regimen involved more frequent injections and, in one comparison, a higher drug dose than Eylea without better results. The speaker questioned whether physicians would choose a treatment that requires more injections but does not improve outcomes.
• The transcript refers to prior trial failures, including DAZZLE, and says the drug had previously been discontinued before being revived. The speaker predicted another failure and said they were considering shorting more shares.
• $15 and $10 were raised as possible downside levels in a rhetorical discussion of where the stock might trade after a failure. They were not presented as formal price targets.

Takeaways

• The bearish case presented is that KOD’s drug may struggle to win adoption if it cannot demonstrate meaningful efficacy or a practical dosing advantage over Eylea.
• For investors assessing the thesis, focus on the actual trial endpoints, whether the treatment meets the required statistical standard, and how its dosing compares with the alternative. The transcript does not establish the outcome of future results.
• The speaker’s stated interest in shorting reflects a highly negative opinion, not a confirmed recommendation or evidence that the stock must decline. The discussion provides no specific timing or price target.